Trial Profile
In-Vivo Vascular Response of Sirolimus-,Paclitaxel- and Zotarolimus-Eluting Stents in Long Lesions Requiring Overlapping. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sirolimus (Primary) ; Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ODESSA
- 01 Jul 2008 New trial record.